Source: Medicines Authority (MT) Revision Year: 2020 Publisher: Ferrer Internacional, S.A., Gran Via Carlos III, 94, 08028 Barcelona, Spain
It must not be administered to patients with known allergy to any ingredient.
It is advisable not to administer Anginovag in conjunction with other topical Treatments.
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Can be interacted by other oral topical products.
Controlled studies in woman or in the animal are not available.
Nevertheless Anginovag is marketed in a flask provided with a dosing valve that permits the application of the adequate quantity of active ingredients with topical activity without systemic absorption.
Consequently it can be used during the pregnancy and lactation.
Anginovag, does not produce any effect over the ability to drive and use of machines.
With not known frequency, blurred vision may occur (see also section 4.4).
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
